ALGO Stumbles as AI Trading and ETF Tools Surge

Allo’s Cell Therapy Progress and Market Implications
Allogene Therapeutics Inc. (ALLO) is advancing its allogeneic cell therapy pipeline, with cema-cel in trials for MRD-positive lymphoma and ALLO-329 in autoimmune disease development. Key updates include the expected release of interim futility data for cema-cel in April 2026, with a focus on outpatient safety and MRD clearance. These developments highlight Allo’s strategic push to expand its presence in the cell and gene therapy space. ALLO-329 aims to validate the Dagger technology platform and reduce reliance on lymphodepletion. Potentially enhancing long-term market viability.

Auto-Execution Protocol Gains Institutional Traction
MCAP Inc. (OTC: MCAP) announced growing adoption of its aRFQ™ protocol, an automated execution tool integrated into QwickRoute. The protocol has attracted over 50 institutional clients and 15 liquidity providers, offering near-zero market impact and faster auction completion times. aRFQ™ enables competitive, multi-dealer liquidity without requiring traders to exit electronic trading workflows, marking a significant shift in how ETF execution is managed. As algorithmic trading volumes rise, this innovation addresses a critical gap in execution efficiency and liquidity access for institutional traders.

Ross Stores Reports Q4 Growth and Shareholder-Focused Strategy
Ross Stores Inc. (ROST) delivered strong fourth-quarter performance, with total sales up 12% to $6.6 billion and a 9% rise in comparable store sales. The company attributed the success to improved merchandising, marketing initiatives, and new store productivity. Ross also increased its quarterly dividend by 10% to $0.45 per share and announced a new $2.55 billion stock buyback program. Management remains optimistic about 2026, with guidance for 7%-8% comparable sales growth in Q1 and a projected 3%-4% increase for the full year. These moves underscore Ross’s commitment to balancing growth and shareholder returns.

Alpha Cognition Advances Alzheimer’s Treatment Commercialization
Alpha Cognition Inc. (ACOG) reported steady growth in ZUNVEYL sales for mild to moderate Alzheimer’s, with 2,038 nursing homes engaged and 70% placing repeat orders. The company secured $38 million in recent fundraising, extending its financial runway to 2027. Management aims to secure a second PBM contract by late 2025 and anticipates regulatory approval in China by year-end. Despite a Q3 net loss, ZUNVEYL’s commercial traction and expansion efforts position Alpha Cognition for potential long-term growth in the neurotherapeutics market.

Binance Launches AI-Driven Trading Capabilities
Binance introduced seven AI agent skills, enabling automated interactions with its trading systems, including market data analysis, advanced order execution, and on-chain contract risk detection. These tools integrate directly into the exchange’s API, offering institutional and sophisticated retail users enhanced automation and security. The initiative represents a broader shift toward AI-driven trading in crypto markets, with implications for liquidity, market efficiency, and regulatory oversight. Analysts suggest this could redefine the competitive landscape for trading platforms.

Market Overview and Price Trends
On March 3, 2026, ALGO remained flat at $0.0862 over the past 24 hours. However, the token has seen a 2.16% decline in the last week and a 22.08% drop over the past year. This underperformance contrasts with the broader market’s interest in institutional-grade trading protocols and AI-driven automation. Investors are closely monitoring how advancements in ETF execution, AI trading tools, and biotech pipelines may influence ALGO’s trajectory in the coming months.